EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that it has received approval from the Drug Controller General of India (DCGI) to proceed with a Phase II clinical evaluation of its Nasulin™ in Type II diabetic patients. Nasulin™ is the Company’s intranasal insulin product utilizing its proprietary CPE-215® delivery technology.
